Addendum

Risankizumab (Crohn disease) – Addendum to Commission A22-133

Status
Status: Commission completed
Project no.
A23-40
Last updated

Report documents

  1. Addendum

    Risankizumab (Crohn disease) – Addendum to Commission A22-133

    published on
    Document type
    PDF document, 548 kB, EN, not accessible

Dossier assessment

Indication:

Adults with moderately to severely active Crohn’s disease

Result of dossier assessment:
  • who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
  • who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy (TNF-alpha antagonist or integrin inhibitor or interleukin inhibitor): after addendum now hint of minor added benefit

Additional information

Federal Joint Committee (G-BA)

2023-06-15 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-40
Commission
Commission awarded on 03.05.2023 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V

    Project no.
    A22-133
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form